Cellular senescence: six decades of discovery and reinvention
- 1European Research Institute for the Biology of Ageing (ERIBA), University of Groningen (RUG), University Medical Center Groningen (UMCG), Groningen, Netherlands
Abstract
Cellular senescence has undergone a remarkable conceptual evolution since its discovery in 1961. Initially described by Hayflick and Moorhead as the finite proliferative lifespan of cultured human cells, senescence was first viewed as a consequence of cellular aging. The identification of telomere shortening, senescence biomarkers, and oncogene- and damage-induced senescence subsequently established its molecular basis and role as a tumor-suppressive stress response. The discovery of the senescence-associated secretory phenotype (SASP) further transformed the field by revealing that senescent cells actively communicate with and remodel their tissue environment. Genetic mouse models later demonstrated causal roles for senescent cells in tissue repair, aging, and age-related disease, while senotherapeutics established senescence as a therapeutic target. Here, we trace the major conceptual transitions that shaped the field, from replicative endpoint to stress-response program, regulator of tissue homeostasis, driver of chronic pathology, and clinically actionable process. We discuss the discoveries, controversies, and technological advances underlying these transitions and how emerging single-cell technologies, precision biomarkers, and targeted interventions are shaping the next era of senescence research.
Related
- Identification and analysis of obesity-cellular senescence associated key genes in metabolic syndrome based on transcriptomic data
- Cellular senescence changes and their association with brain structure in schizophrenia and major depressive disorder
- Macrophage senescence and senescence-like states in senile osteoporosis: cellular cross-talk and therapeutic perspectives
- Methylation-associated Gene Expression (MaGE): a non-invasive, in vivo measure of cellular senescence.
- Alternative Isoforms as Molecular Modulators of Cellular Senescence in Cancer
BibTeX
@article{klaver2026cellular,
title = {{Cellular senescence: six decades of discovery and reinvention}},
author = {Myrthe Klaver and Lotte Sophie Steeneken and Naomi Veeningen and Abdullah Altulea and Marco Demaria},
journal = {The EMBO Journal},
year = {2026},
month = oct,
doi = {10.1038/s44318-026-00922-w},
url = {https://doi.org/10.1038/s44318-026-00922-w},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cellular senescence: six decades of discovery and reinvention
AU - Myrthe Klaver
AU - Lotte Sophie Steeneken
AU - Naomi Veeningen
AU - Abdullah Altulea
AU - Marco Demaria
PY - 2026
DA - 2026/10/02
JO - The EMBO Journal
DO - 10.1038/s44318-026-00922-w
UR - https://doi.org/10.1038/s44318-026-00922-w
AB - Cellular senescence has undergone a remarkable conceptual evolution since its discovery in 1961. Initially described by Hayflick and Moorhead as the finite proliferative lifespan of cultured human cells, senescence was first viewed as a consequence of cellular aging. The identification of telomere shortening, senescence biomarkers, and oncogene- and damage-induced senescence subsequently established its molecular basis and role as a tumor-suppressive stress response. The discovery of the senescence-associated secretory phenotype (SASP) further transformed the field by revealing that senescent cells actively communicate with and remodel their tissue environment. Genetic mouse models later demonstrated causal roles for senescent cells in tissue repair, aging, and age-related disease, while senotherapeutics established senescence as a therapeutic target. Here, we trace the major conceptual transitions that shaped the field, from replicative endpoint to stress-response program, regulator of tissue homeostasis, driver of chronic pathology, and clinically actionable process. We discuss the discoveries, controversies, and technological advances underlying these transitions and how emerging single-cell technologies, precision biomarkers, and targeted interventions are shaping the next era of senescence research.
SN - 0261-4189
SN - 1460-2075
ER -